Literature DB >> 24237428

[Distribution of blaOXA genes in Acinetobacter baumannii strains: a multicenter study].

Ihsan Hakkı Ciftci1, Gülşah Aşık, Engin Karakeçe, Lütfiye Oksüz, Server Yağcı, Emel Sesli Çetin, Mehmet Ozdemir, Ali Rıza Atasoy, Esra Koçoğlu, Mustafa Gül, Muhammet Güzel Kurtoğlu, Fatma Köksal Çakırlar, Adnan Seyrek, Mustafa Berktaş, Bilge Gültepe, Ahmet Ayyildiz.   

Abstract

Acinetobacter baumannii is the most important agent of nosocomial infections within the Acinetobacter genus. This gram-negative coccobacillus is intrinsically resistant to many antibiotics used in antimicrobial therapy, and capable of developing resistance including carbapenems. The objective of this study was to develop a multiplex real time polymerase chain reaction (qPCR) kit for OXA subgroups in A.baumannii, and to investigate the distribution of OXA subgroups in A.baumannii strains isolated from geographically different regions of Turkey. A total of 834 A.baumannii clinical isolates collected from different state and university medical centers in 13 provinces (Afyonkarahisar, Ankara, Bolu, Elazig, Erzurum, Isparta, Istanbul, Kahramanmaras, Konya, Sakarya, Van) between 2008-2011, were included in the study. The isolates were identified by conventional methods and automated systems [Vitek2 (bioMerieux, ABD) and Phoenix (BD Diagnostic, MD)]. The susceptibility profiles of the isolates were studied with automated systems and standard disc diffusion method. All samples were subjected to qPCR to detect blaOXA-51-like, blaOXA-23-like and blaOXA-58-like genes. A conventional PCR method was also used to detect blaOXA-24-like gene. The resistance rates observed during the study period were as follows: 96.8% for amoxicillin-clavulanate, 86.8% for ciprofloxacin, 74.7% for gentamicin, 71.7% for amikacin, 73.5% for cefaperozone-sulbactam, 72.1% for imipenem and 73% for meropenem. Six hundred and two (72.2 %) isolates were resistant to both imipenem and meropenem. Colistin was found to be the most effective antibiotic against A.baumannii isolates with 100% susceptibility rate. All isolates were positive for blaOXA-51-like, however blaOXA-24-like gene could not be demonstrated in any isolate. Total positivity rates of blaOXA-23-like and blaOXA-58-like genes were found as 53.7% and 12.5%, respectively, while these rates were 74.4% and 17.3% in carbapenem-resistant isolates, respectively. Twenty-five isolates were positive for both blaOXA-23-like and blaOXA-58-like genes. All of the carbapenem-resistant isolates have OXA type genes with the exception of blaOXA-24-like gene. The positivity rates for blaOXA-23-like and blaOXA-58-like genes varied for each center. In addition, there was a decrease in the frequency of blaOXA-58-like gene, however both blaOXA-23-like gene and carbapenem resistance rates increased during the study period. In conclusion, high rates of resistance to carbapenems were also remarkable but A.baumannii strains keep on sensitivity to colistin. Both blaOXA-23-like and blaOXA-58-like genes were shown to be widespread in carbapenem-resistant A.baumannii clinical isolates. However, blaOXA-23-like gene positive strains were increased throughout the study. Currently, multiplex qPCR is the best way for rapid diagnosis of resistant bacteria for prevention of hospital-acquired infections. The multiplex qPCR kit developed in this study could be useful for rapid diagnosis and identify the frequencies of blaOXA-23-like, blaOXA-51-like and blaOXA-58-like genes in carbapenem-resistant A.baumannii clinical isolates.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24237428     DOI: 10.5578/mb.6388

Source DB:  PubMed          Journal:  Mikrobiyol Bul        ISSN: 0374-9096            Impact factor:   0.622


  8 in total

1.  Modifying enzymes related aminoglycoside: analyses of resistant Acinetobacter isolates.

Authors:  Ali Riza Atasoy; Ihsan Hakki Ciftci; Mustafa Petek
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Molecular Detection of Class-D OXA Carbapenemase Genes in Biofilm and Non-Biofilm Forming Clinical Isolates of Acinetobacter baumannii.

Authors:  Omid Azizi; Mohammad Reza Shakibaie; Farzan Modarresi; Fereshteh Shahcheraghi
Journal:  Jundishapur J Microbiol       Date:  2015-01-12       Impact factor: 0.747

Review 3.  Epidemiology of carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean countries.

Authors:  Nassima Djahmi; Catherine Dunyach-Remy; Alix Pantel; Mazouz Dekhil; Albert Sotto; Jean-Philippe Lavigne
Journal:  Biomed Res Int       Date:  2014-05-13       Impact factor: 3.411

4.  Subtypes, resistance and virulence platforms in extended-drug resistant Acinetobacter baumannii Romanian isolates.

Authors:  Irina Gheorghe; Ilda Czobor Barbu; Marius Surleac; Ionela Sârbu; Laura Ioana Popa; Simona Paraschiv; Yu Feng; Veronica Lazăr; Mariana Carmen Chifiriuc; Dan Oţelea; Zong Zhiyong
Journal:  Sci Rep       Date:  2021-06-24       Impact factor: 4.379

5.  Association of doripenem resistance with OXA-type carbapenemases in Acinetobacter baumannii isolates.

Authors:  Huseyin-Agah Terzi; Ali-Rıza Atasoy; Sadiye-Berna Aykan; Engin Karakece; Gulsah Asık; Ihsan-Hakkı Ciftci
Journal:  Saudi Med J       Date:  2016-01       Impact factor: 1.484

6.  Prevalence of Acinetobacter baumannii bacteremia in intensive care units of Ibn Rochd University Hospital, Casablanca.

Authors:  Assiya El Kettani; Fakhreddine Maaloum; Idrissa Diawara; Khalid Katfy; Nadia Harrar; Khalid Zerouali; Houria Belabbes; Naima Elmdaghri
Journal:  Iran J Microbiol       Date:  2017-12

Review 7.  Antibiotic Resistance Profiles, Molecular Mechanisms and Innovative Treatment Strategies of Acinetobacter baumannii.

Authors:  Corneliu Ovidiu Vrancianu; Irina Gheorghe; Ilda Barbu Czobor; Mariana Carmen Chifiriuc
Journal:  Microorganisms       Date:  2020-06-21

Review 8.  Understanding the Epidemiology of Multi-Drug Resistant Gram-Negative Bacilli in the Middle East Using a One Health Approach.

Authors:  Iman Dandachi; Amer Chaddad; Jason Hanna; Jessika Matta; Ziad Daoud
Journal:  Front Microbiol       Date:  2019-08-23       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.